KYNB logo

KYNTRA BIO INC

KYNBNASDAQ
🏆 #4632 by market capEarnings Nov 9 · PostUS Equity
$4.72▲ $0.22 (+4.89%)
🌅 Pre-market$4.76▲ 0.85%Regular close · extended-hours price shown
🔔
Track KYNB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.9%
7d▼ 9.6%
14d▼ 16.5%
30d▼ 34.9%
ytd▼ 46.1%
1y▼ 56.4%
🏦Market Cap
$19M
Small Cap
📈Revenue Growth (YoY)
-91.4%
Declining
📊Gross Margin
40.7%
Healthy
💵FCF Margin
333.0%
Strong
⚖️P/S Ratio
3.9x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$4.37 – $4.72
52-Week Range
$4.32 – $11.39
Volume (shares)
12,936
Avg Volume (shares)
—
Shares Outstanding
4.0M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
—
P/E Ratio
0.1
P/S Ratio
3.9x
EPS (TTM)
$45.30
Dividend Yield
—
Dilution (1yr)
+0.2%
KYNB logo

KYNTRA BIO INC

KYNB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▼ −78.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.4%▲ +92.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$46M▼ −69.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −96.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.0M▲ +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$48M▲ +$70M YoY
StockOtter · stockotter.space

About KYNTRA BIO INC

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
10 analysts
Strong Buy3
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

🚀
Defense World·20d ago

Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast

Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the stre

GlobeNewsWire·28d ago

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee e

GlobeNewsWire·Sep 2

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference b

GlobeNewsWire·Aug 31

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially

Seeking Alpha·Aug 14

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Zacks Investment Research·Aug 13

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.